Views & Analysis | Perspectives on pharma industry issues

R&D

Gravity is an experimental variable pharma has rarely been a...

Microgravity should not be a destination for pharmaceutical R&D, but another experimental environment.

Digital

Sponsored

Antiviral development in the age of AI: From pre-IND to earl...

hVIVO experts discuss how advancements in AI and machine learning are pushing industry beyond the bounds of a traditional "one virus, one drug" model.

Market Access

Biotech's next growth cycle: Renewed confidence comes with c...

Renewed confidence across biopharma is welcome and long overdue after a prolonged period of constraint. But confidence alone is not enough.

Oncology

The future of oncology is adaptive: What ESMO 2026 revealed ...

Across tumours, three developments repeatedly surfaced throughout the congress, each reflecting a notable transition in how cancer is being managed.

Market Access

Sponsored

Solution Spotlight: Acumetis Model Builder

Acumetis Model Builder is a web-based platform that generates complete, formula-linked Excel cost-effectiveness and budget impact models in minutes.

Articles

Rare disease awareness: Alkaptonuria

Are enough questions being asked of patients who don’t present with typical symptoms of common diseases? Oliver Timmis of the AKU society doesn’t think so and here he explains why doing so could increase rare disease recognition and reduce patient isolation. There are approximately 7000 rare diseases and many patients suffering from them unfortunately face years of misdiagnosis and...

Articles

Rare diseases, orphan drugs and parent companies

Catherine McLoughlin discusses the investments of pharma and biotech companies in the orphan drug market. If, early on in my career as a lawyer in the life sciences sector, I had a £1.00 for every deal that I did for a biotech company...

Articles

Rare diseases part 1: posing questions that are difficult to...

Starting off our rare diseases focus month, Neil Dickinson discusses the impact of orphan drug development, looking at legislation changes and his own personal experiences. The pharmaceutical industry has always been different to most other commercial sectors and almost every point of difference...

Sales & Marketing

Sponsored

Solution Spotlight: BrandPRO Biopharma

Strong strategy on paper can unravel when priorities collide. BrandPRO Biopharma gives pharmaceutical teams a place to put their decisions to the test

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Digital

Sponsored

Antiviral development in the age of AI: From pre-IND to earl...

hVIVO experts discuss how advancements in AI and machine learning are pushing industry beyond the bounds of a traditional "one virus, one drug" model.

Digital